Stocks
United Therapeutics Corporation

United Therapeutics CorporationUTHR

NASDAQHealthcareBiotechnology$497.11+0.62%

Price as of · delayed, not real-time

A biopharmaceutical company focused on developing and commercializing therapies for chronic and life-threatening conditions, primarily in pulmonary arterial hypertension and other orphan diseases. Investors track United Therapeutics for its niche pipeline and FDA-approved treatments like Remodulin and Tyvaso, which dominate specialized markets with limited competition.

Market Cap: $23.5B52W Range: $396.12-$609.35

Congressional Interest in United Therapeutics Corporation (UTHR)

6 members of Congress have disclosed 36 trades in United Therapeutics Corporation (UTHR), a Healthcare company. The buy/sell breakdown shows 22 purchases versus 14 sales, indicating net buying interest from lawmakers. All data is sourced from STOCK Act periodic transaction reports filed with Congress.

Total Disclosures
36
Unique Politicians
6
Buys
22
Sells
14

Who in Congress Is Trading UTHR?

2025-10-31$1K-$15K
Stock
2025-10-30$1K-$15K
Stock
2025-10-30$1K-$15K
Stock
2025-10-27$1K-$15K
Stock
2025-08-22$50K-$100K
Stock
2025-06-11$1K-$15K
Stock
2024-12-13$50K-$100K
Stock
2024-12-13$1K-$15K
Stock
2024-11-20$15K-$50K
Stock
2024-11-20$15K-$50K
Stock
2024-11-19$100K-$250K
Stock
2024-11-06$15K-$50K
Stock
2021-07-15$15K-$50K
Stock
2021-06-30$15K-$50K
Stock
2021-06-30$15K-$50K
Stock
2021-06-29$15K-$50K
Stock
2021-05-27$15K-$50K
Stock
2021-05-26$15K-$50K
Stock
2021-05-25$1K-$15K
Stock
2021-05-21$15K-$50K
Stock
2021-03-15$1K-$15K
Stock
2019-03-06$1K-$15K
Stock
2016-09-01$15K-$50K
Stock
2015-05-27$1K-$15K
Stock
2011-12-12-$837.74
Stock
2011-12-12$-837.74
Stock
2011-12-12$837.74
Stock
2011-06-10
Stock
2011-06-10
Stock
2010-01-12-$1,079.80
Stock
2010-01-10-1,407.20
Stock
2009-08-09-1323.07
Stock
2009-08-09-$1323.07
Stock
2009-02-10700.93
Stock
2009-02-10700.93
Stock
2009-01-10-$724.76
Stock